Iida M - Search Results

1

Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. Brand TM, et al. Among authors: iida m. Sci Signal. 2021 Nov 9;14(708):eabn0168. doi: 10.1126/scisignal.abn0168. Epub 2021 Nov 9. Sci Signal. 2021. PMID: 34752142 Free PMC article. No abstract available.

2

Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.

Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, Harari PM. Wheeler DL, et al. Among authors: iida m. Cancer Biol Ther. 2009 Apr;8(8):696-703. doi: 10.4161/cbt.8.8.7903. Epub 2009 Apr 22. Cancer Biol Ther. 2009. PMID: 19276677 Free PMC article.

3

The role of Src in solid tumors.

Wheeler DL, Iida M, Dunn EF. Wheeler DL, et al. Among authors: iida m. Oncologist. 2009 Jul;14(7):667-78. doi: 10.1634/theoncologist.2009-0009. Epub 2009 Jul 6. Oncologist. 2009. PMID: 19581523 Free PMC article. Review.

4

Nuclear EGFR contributes to acquired resistance to cetuximab.

Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Li C, et al. Among authors: iida m. Oncogene. 2009 Oct 29;28(43):3801-13. doi: 10.1038/onc.2009.234. Epub 2009 Aug 17. Oncogene. 2009. PMID: 19684613 Free PMC article.

5

Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors.

Kruser TJ, Wheeler DL, Armstrong EA, Iida M, Kozak KR, van der Kogel AJ, Bussink J, Coxon A, Polverino A, Harari PM. Kruser TJ, et al. Among authors: iida m. Clin Cancer Res. 2010 Jul 15;16(14):3639-47. doi: 10.1158/1078-0432.CCR-09-3385. Epub 2010 May 27. Clin Cancer Res. 2010. PMID: 20507929 Free PMC article.

6

Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.

Li C, Iida M, Dunn EF, Wheeler DL. Li C, et al. Among authors: iida m. Radiother Oncol. 2010 Nov;97(2):330-7. doi: 10.1016/j.radonc.2010.06.010. Radiother Oncol. 2010. PMID: 20667610 Free PMC article.

7

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL. Dunn EF, et al. Among authors: iida m. Oncogene. 2011 Feb 3;30(5):561-74. doi: 10.1038/onc.2010.430. Epub 2010 Oct 18. Oncogene. 2011. PMID: 20956938 Free PMC article.

8

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.

Brand TM, Iida M, Wheeler DL. Brand TM, et al. Among authors: iida m. Cancer Biol Ther. 2011 May 1;11(9):777-92. doi: 10.4161/cbt.11.9.15050. Epub 2011 May 1. Cancer Biol Ther. 2011. PMID: 21293176 Free PMC article. Review.

9

Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.

Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL. Brand TM, et al. Among authors: iida m. Cancer Biol Ther. 2011 Sep 1;12(5):436-46. doi: 10.4161/cbt.12.5.16394. Epub 2011 Sep 1. Cancer Biol Ther. 2011. PMID: 21725209 Free PMC article.

10

The nuclear epidermal growth factor receptor signaling network and its role in cancer.

Brand TM, Iida M, Li C, Wheeler DL. Brand TM, et al. Among authors: iida m. Discov Med. 2011 Nov;12(66):419-32. Discov Med. 2011. PMID: 22127113 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,300 results

Search Page

Filters